**BACKGROUND**

Introduction

- Despite the availability of several new antiepileptic medications (ASMs), approximately 30% of patients with epilepsy experience treatment-resistant epilepsy (TRE). XEN1101, the first ASM being developed with a new mechanism of action, is being rapidly advancing in the development of epilepsy.

**METHODS**

- Chung SS, et al. 5 ASMs that more of subjects were on concomitant ASMs during the study. Clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment was evaluated in adults with >5 seizures/month (TOLE) and >10 seizures/month (TOLE-SE)).

**CONCLUSIONS**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**RESULTS**

- Efficacy Results: Median Percent Change (MPC) from Baseline2

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**Prior ASMs (Safety Population)**

| Table 3. Antiepileptic Medications Taken Prior to Study (Including Ongoing Medication) |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| **Phenobarbital** | **Lamotrigine** | **Lacosamide** | **Perampanel** | **Other Antiepileptic Meds** |
| Placebo (N=114) | 3 (2.6) | 7 (6.1) | 2 (1.7) | 1 (0.9) |
| XEN1101 10mg (N=51) | 3 (6.0) | 8 (15.7) | 2 (3.9) | 2 (3.9) |
| XEN1101 20mg (N=51) | 2 (3.9) | 9 (17.6) | 2 (3.9) | 2 (3.9) |

**Safety Population**

- Median monthly FOS reduction was 60.9% for subjects with 1 30.4% at baseline compared to 25.0% in the DBP; n=112 at baseline. Concomitant ASMs Sub 19.

**Concomitant ASMs (Safety Population)**

- Median monthly FOS reduction was 60.9% for subjects with 1 30.4% at baseline compared to 25.0% in the DBP; n=112 at baseline. Concomitant ASMs Sub 19.

**DEMOGRAPHICS**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**Efficacy Results: Median Percent Change (MPC) from Baseline**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**Prior Failed ASMs (Safety Group)**

- Median monthly FOS reduction was 60.9% for subjects with 1 30.4% at baseline compared to 25.0% in the DBP; n=112 at baseline. Concomitant ASMs Sub 19.

**Baseline Seizure Sub-Group Analysis**

- Median monthly FOS reduction was 60.9% for subjects with 1 30.4% at baseline compared to 25.0% in the DBP; n=112 at baseline. Concomitant ASMs Sub 19.

**RESULTS**

- Efficacy Results: Median Percent Change (MPC) from Baseline2

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**CONCLUSIONS**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**METHODS**

- Chung SS, et al. 5 ASMs that more of subjects were on concomitant ASMs during the study. Clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment was evaluated in adults with >5 seizures/month (TOLE) and >10 seizures/month (TOLE-SE)).

**CONCLUSIONS**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**RESULTS**

- Efficacy Results: Median Percent Change (MPC) from Baseline2

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**CONCLUSIONS**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**RESULTS**

- Efficacy Results: Median Percent Change (MPC) from Baseline2

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.

**CONCLUSIONS**

- XEN1101 demonstrated a dose-dependent reduction from baseline in median monthly frequency of FOS at 39.4% (30 mg) and 56.4% (60 mg) in subgroups of patients with 6.5 seizures/month, and in patients that failed 2 ASMs or were on 2 concomitant ASMs by 28.6% and 45.2%, respectively.